The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases

References

• Bergman L, Seregard S, Nilsson B, et al. (2002). Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 43:2579–83.
   PubMed Web of Science ®Google Scholar
• Kujala E, Makitie T, Kivela T. (2003). Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44:4651–9.
   PubMed Web of Science ®Google Scholar
• Diener-West M, Reynolds SM, Agugliaro DJ, et al. (2005). Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 123:1639–43.
   PubMed Web of Science ®Google Scholar
• Rietschel P, Panageas KS, Hanlon C, et al. (2005). Variates of survival in metastatic uveal melanoma. J Clin Oncol 23:8076–80.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Egan KM, Seddon JM, et al. (1991). Survival of patients with metastases from uveal melanoma. Ophthalmology 98:383–9. discussion 390.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Legha SS, Mavligit G, et al. (1995). Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76:1665–70.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Papadopoulos N, Plager C, et al. (2003). Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 13:303–6.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Vaubel J, Mohr P, et al. (2015). Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One 10:e0118564.
   PubMed Web of Science ®Google Scholar
• Kottschade LA, McWilliams RR, Markovic SN, et al. (2016). The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res 26:300–3.
   PubMed Web of Science ®Google Scholar
• Mariani P, Piperno-Neumann S, Servois V, et al. (2009). Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol 35:1192–7.
   PubMed Web of Science ®Google Scholar
• Peters S, Voelter V, Zografos L, et al. (2006). Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 17:578–83.
   PubMed Web of Science ®Google Scholar
• Gonsalves CF, Eschelman DJ, Thornburg B, et al. (2015). Uveal melanoma metastatic to the liver: chemoembolization with 1,3-bis-(2-chloroethyl)-1-nitrosourea. AJR Am J Roentgenol 205:1–5.
   Web of Science ®Google Scholar
• Valpione S, Aliberti C, Parrozzani R, et al. (2015). A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. Melanoma Res 25:164–8.
   PubMed Web of Science ®Google Scholar
• Aust JB, Ausman RK. (1960). The technique of liver perfusion. Cancer Chemother Rep 10:23–33.
   PubMedGoogle Scholar
• Bartlett DL, Libutti SK, Figg WD, et al. (2001). Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129:176–87.
   PubMed Web of Science ®Google Scholar
• Grover A, Alexander HR, Jr. (2004). The past decade of experience with isolated hepatic perfusion. Oncologist 9:653–64.
   PubMed Web of Science ®Google Scholar
• Feldman ED, Wu PC, Beresneva T, et al. (2004). Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 8:200–7.
   PubMed Web of Science ®Google Scholar
• Alexander HR, Libutti SK, Bartlett DL, et al. (2000). A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6:3062–70.
   PubMed Web of Science ®Google Scholar
• Alexander HR, Jr., Libutti SK, Pingpank JF, et al. (2003). Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 9:6343–9.
   PubMed Web of Science ®Google Scholar
• Noter SL, Rothbarth J, Pijl ME, et al. (2004). Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 14:67–72.
   PubMed Web of Science ®Google Scholar
• Pingpank JF, Libutti SK, Chang R, et al. (2005). Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23:3465–74.
   PubMed Web of Science ®Google Scholar
• Rizell M, Mattson J, Cahlin C, et al. (2008). Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res 18:120–6.
   PubMed Web of Science ®Google Scholar
• Verhoef C, de Wilt JH, Brunstein F, et al. (2008). Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol 15:1367–74.
   PubMed Web of Science ®Google Scholar
• van Iersel LB, Hoekman EJ, Gelderblom H, et al. (2008). Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 15:1891–8.
   PubMed Web of Science ®Google Scholar
• van Etten B, de Wilt JH, Brunstein F, et al. (2009). Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. Eur J Surg Oncol 35:539–45.
   PubMed Web of Science ®Google Scholar
• Ben-Shabat I, Belgrano V, Ny L, et al. (2016). Long-term follow-up evaluation of 68 patients with uveal melanoma liver metastases treated with isolated hepatic perfusion. Ann Surg Oncol 23:1327–34.
   PubMed Web of Science ®Google Scholar
• Ben-Shabat I, Hansson C, Sternby Eilard M, et al. (2015). Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma. J Vis Exp 95:52490.
   Google Scholar
• Olofsson R, Mattsson J, Lindner P. (2013). Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. Int J Hyperthermia 29:551–7.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. (2004). Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–13.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–47.
   PubMed Web of Science ®Google Scholar
• Skarsgard LD, Skwarchuk MW, Vinczan A, et al. (1995). The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 15:219–23.
   PubMed Web of Science ®Google Scholar
• Kelley ST, Menon C, Buerk DG, et al. (2002). Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model. Surgery 132:252–8.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Sosman JA, Quevedo F. (2013). Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J Clin Oncol 31:CRA9003.
   PubMedGoogle Scholar
• Olofsson R, Ny L, Eilard MS, et al. (2014). Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials 15:317.
   PubMed Web of Science ®Google Scholar